Konstantinos Chouliaras1, Rebecca Senehi1, Cecilia G Ethun2, George Poultsides3, Valerie Grignol4, Callisia N Clarke5, Kevin K Roggin6, Ryan C Fields7, Patrick B Schwartz8, Sean M Ronnekleiv-Kelly8, Ralph D'Agostino9, Emily N Johnson9, Edward A Levine1, Kenneth Cardona2, Konstantinos I Votanopoulos1. 1. Division of Surgical Oncology, Department of Surgery, Wake Forest University, Winston-Salem, North Carolina. 2. Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Department of Surgery, Stanford University, Palo Alto, California. 4. Department of Surgery, The Ohio State University, Columbus, Ohio. 5. Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. 6. Department of Surgery, University of Chicago, Chicago, Illinois. 7. Department of Surgery, Washington University, St. Louis, Missouri. 8. Department of Surgery, University of Wisconsin, Madison, Wisconsin. 9. Department of Biostatistical Sciences, Wake Forest University, Winston-Salem, North Carolina.
Abstract
BACKGROUND: The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear. METHODS: A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded. RESULTS: Total 425 patients were included, 56 in the neoadjuvant radiation group (neo-RT), 75 in the adjuvant radiation group (adj-RT), and 294 in the no radiotherapy group (no-RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj-RT and 59 neo-RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence-free survival (RFS) was 35.9 months (no-RT) vs 33.5 months (neo-RT) and 27.2 months (adj-RT), P = .43 and P = .84, respectively. In the PSM, RFS was 17.6 months (no-RT) vs 33.9 months (neo-RT), P = .28 and 19 months (no-RT) vs 27.2 months (adj-RT), P = .1. CONCLUSIONS: Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.
BACKGROUND: The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear. METHODS: A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded. RESULTS: Total 425 patients were included, 56 in the neoadjuvant radiation group (neo-RT), 75 in the adjuvant radiation group (adj-RT), and 294 in the no radiotherapy group (no-RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj-RT and 59 neo-RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence-free survival (RFS) was 35.9 months (no-RT) vs 33.5 months (neo-RT) and 27.2 months (adj-RT), P = .43 and P = .84, respectively. In the PSM, RFS was 17.6 months (no-RT) vs 33.9 months (neo-RT), P = .28 and 19 months (no-RT) vs 27.2 months (adj-RT), P = .1. CONCLUSIONS: Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.
Authors: M Toulmonde; S Bonvalot; P Méeus; E Stoeckle; O Riou; N Isambert; E Bompas; M Jafari; C Delcambre-Lair; E Saada; A Le Cesne; C Le Péchoux; J Y Blay; S Piperno-Neumann; C Chevreau; J O Bay; V Brouste; P Terrier; D Ranchère-Vince; A Neuville; A Italiano Journal: Ann Oncol Date: 2014-03 Impact factor: 32.976
Authors: Robert A Zlotecki; Teri S Katz; Christopher G Morris; D Scott Lind; Steven N Hochwald Journal: Am J Clin Oncol Date: 2005-06 Impact factor: 2.339
Authors: E Gortzak; A Azzarelli; J Buesa; V H Bramwell; F van Coevorden; A N van Geel; A Ezzat; A Santoro; J W Oosterhuis; M van Glabbeke; A Kirkpatrick; J Verweij Journal: Eur J Cancer Date: 2001-06 Impact factor: 9.162
Authors: Alberto Bossi; Ivo De Wever; Erik Van Limbergen; Bianca Vanstraelen Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: Markus Albertsmeier; Alexandra Rauch; Falk Roeder; Sandro Hasenhütl; Sebastian Pratschke; Michaela Kirschneck; Alessandro Gronchi; Nina L Jebsen; Philippe A Cassier; Paul Sargos; Claus Belka; Lars H Lindner; Jens Werner; Martin K Angele Journal: Ann Surg Oncol Date: 2017-09-11 Impact factor: 5.344
Authors: Daniel P Nussbaum; Christel N Rushing; Whitney O Lane; Diana M Cardona; David G Kirsch; Bercedis L Peterson; Dan G Blazer Journal: Lancet Oncol Date: 2016-05-17 Impact factor: 41.316
Authors: Mary Koshy; Jerome C Landry; Joshua D Lawson; Charles A Staley; Natia Esiashvili; Rebecca Howell; Shahram Ghavidel; Lawrence W Davis Journal: Sarcoma Date: 2003
Authors: Steven D Forsythe; Hemamylammal Sivakumar; Richard A Erali; Nadeem Wajih; Wencheng Li; Perry Shen; Edward A Levine; Katherine E Miller; Aleksander Skardal; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2022-07-03 Impact factor: 4.339
Authors: Andrej Ozaniak; Jitka Smetanova; Robin Bartolini; Michal Rataj; Linda Capkova; Jaromir Hacek; Martina Fialova; Lenka Krupickova; Ilja Striz; Robert Lischke; Jirina Bartunkova; Zuzana Strizova Journal: J Cancer Res Clin Oncol Date: 2022-08-20 Impact factor: 4.322
Authors: Derek J Erstad; Yi-Ju Chiang; Russell G Witt; Brandon Cope; Elise F Nassif; Christopher P Scally; Keila E Torres; Barry W Feig; Kelly K Hunt; Andrew J Bishop; B Ashleigh Guadagnolo; Christina L Roland; Emily Z Keung Journal: Ann Surg Oncol Date: 2022-09-17 Impact factor: 4.339
Authors: Michael J Littau; Sujay Kulshrestha; Corinne Bunn; Sonya Agnew; Patrick Sweigert; Fred A Luchette; Marshall S Baker Journal: Am J Surg Date: 2020-11-23 Impact factor: 2.565
Authors: Michael J Littau; Sujay Kulshrestha; Corinne Bunn; Sonya Agnew; Patrick Sweigert; Fred A Luchette; Marshall S Baker Journal: Am J Surg Date: 2020-11-13 Impact factor: 2.565